Next Lesson - Epilepsy and Anti-epileptic Drugs
Core
A Shared Synapse Map
Psychopharmacology is easier when medicines are placed on a normal synapse before drug names are learned. Monoamine neurones (nerve cells that use serotonin, dopamine or noradrenaline) synthesise transmitter in the cytosol (the fluid inside the cell), load it into vesicles (small storage packets) through the vesicular monoamine transporter, and release it when an action potential opens voltage-gated calcium channels (channels that open when the voltage across the cell membrane changes). Serotonin is made from tryptophan, an amino acid, while dopamine and noradrenaline share a pathway beginning with tyrosine, another amino acid. Released transmitter binds receptors on nearby cells and autoreceptors (receptors on the releasing terminal itself, which sense how much transmitter has been released).
Transporters then retrieve much of the released monoamine. The serotonin transporter (SERT) returns serotonin to the presynaptic terminal (the releasing end of the neurone, before the synapse). The noradrenaline transporter (NET, called the norepinephrine transporter in the US) retrieves noradrenaline and can also influence dopamine clearance in regions with little dopamine transporter. Recovered transmitter can be repackaged or metabolised intracellularly by monoamine oxidase (MAO), an enzyme that breaks monoamines down inside the neurone. These are separate steps: blocking reuptake prolongs extracellular transmitter availability (how long transmitter stays outside the cell), while inhibiting monoamine oxidase reduces intracellular breakdown (breakdown inside the cell) and expands releasable stores over time.
Changing transmitter concentration is only the first layer. Monoamine receptors differ in location, G-protein coupling (the way a receptor passes its signal into the cell through G-proteins) and feedback role. An immediate rise at a synapse can produce early physiological or adverse effects, yet repeated exposure can alter autoreceptor feedback, receptor abundance, gene transcription (copying genes into RNA) and synaptic plasticity (changes in the strength of connections between neurones). A transporter block therefore begins quickly, but the resulting network does not remain biologically static.
Reuptake inhibitors act at the plasma-membrane transporter; monoamine-oxidase inhibitors act on intracellular metabolism.
SimpleMed original educational diagram
Antidepressant Targets
Selective serotonin reuptake inhibitors (SSRIs) inhibit SERT more strongly than NET at usual exposures (typical doses). Serotonin and noradrenaline reuptake inhibitors (SNRIs) inhibit both SERT and NET, although the balance varies between molecules and with concentration. Tricyclic antidepressants also inhibit SERT and NET (they are named for their three-ringed chemical structure), but many additionally antagonise (block) muscarinic acetylcholine receptors, histamine H1 receptors and alpha-1 adrenoceptors (receptors for noradrenaline, found for example on blood vessels). Drugs in one class share a main target but are not identical, so a class name is a useful starting point, not a full description of the pharmacology.
Off-target binding (binding to receptors other than the intended transporters) predicts much of the tricyclic burden (the unwanted effects). Muscarinic antagonism can reduce salivation, slow gut and bladder emptying, blur near vision and impair cognition. H1 antagonism supports sedation and appetite increase. Alpha-1 antagonism reduces vascular tone and can cause postural hypotension. Blocking the fast sodium channels in the heart can slow the spread of electrical impulses through it (conduction), a mechanism distinct from reuptake inhibition. A single molecule can therefore combine wanted transporter action with several receptor and ion-channel effects.
Monoamine-oxidase inhibitors reduce enzymatic monoamine breakdown rather than blocking the uptake transporter. The enzyme comes in two forms. Monoamine oxidase A (MAO-A) preferentially metabolises serotonin and noradrenaline as well as dopamine; monoamine oxidase B (MAO-B) is important in dopamine metabolism and has different tissue distribution. Selectivity and reversibility differ between medicines. The shared lesson is that metabolism inhibition changes how transmitter is handled inside the neurone and how much is available, so metabolism inhibition is not the same as leaving a single burst of released transmitter in the synaptic cleft (the gap between neurones) for longer.
None of these mechanisms shows that more monoamine instantly produces a full clinical response. Transmitter availability, receptor occupancy and downstream circuit adaptation sit at different levels of explanation. The diagnosis, choice of medicine and stepped treatment belong in the psychiatry lessons; here the aim is to locate the molecular action accurately.
Dopamine Pathways and D2 Blockade
Four dopamine pathways organise introductory antipsychotic pharmacology (antipsychotics are medicines that treat psychosis, for example in schizophrenia), because blocking D2 receptors has a different effect in each. The mesolimbic pathway projects from the ventral tegmental area (a midbrain region rich in dopamine neurones) to limbic structures (brain regions involved in emotion and reward) including the nucleus accumbens (a reward centre deep in the forebrain). The mesocortical pathway projects from the ventral tegmental area towards the prefrontal cortex (the front part of the frontal lobe, involved in planning and decision-making). The nigrostriatal pathway runs from the substantia nigra pars compacta (a dopamine-rich part of the midbrain) to the dorsal striatum (part of the basal ganglia) and participates in movement. The tuberoinfundibular pathway runs from the hypothalamus towards the pituitary portal system (the small blood vessels that carry signals from the hypothalamus to the pituitary gland), where dopamine normally restrains the release of prolactin, a hormone that stimulates milk production.
D2 receptor antagonism is a central mechanism for many antipsychotic medicines, but location determines consequence. Mesolimbic D2 antagonism is linked to useful antipsychotic action. Nigrostriatal blockade disrupts dopamine-acetylcholine balance in motor circuits and predicts acute dystonia (sudden painful muscle spasms), akathisia (inner restlessness with an urge to move), parkinsonism (tremor, rigidity and slow movement) and, after prolonged exposure in susceptible people, tardive dyskinesia (involuntary repetitive movements, often of the face and mouth). Tuberoinfundibular blockade removes tonic (continuous) prolactin inhibition and can cause hyperprolactinaemia (a high blood prolactin level).
D2 blockade does not simply correct every dopamine pathway, and the mesocortical pathway is one example. Dopamine signalling in cortex is more complex, and existing cognitive or negative symptoms may not follow the same rule as mesolimbic effects. Second-generation antipsychotics also have diverse affinities at D2, serotonin, histamine, muscarinic and adrenergic receptors. Some are partial D2 agonists (they activate the receptor, but less than dopamine does). Treating second-generation antipsychotics as one uniform receptor profile hides rather than explains their differences.
The same D2 blockade has different effects because each dopamine pathway serves a different circuit.
SimpleMed original educational diagram
GABA-A Modulation
GABA-A receptors are ligand-gated chloride channels (channels that open when a signalling molecule binds) assembled from several subunits (protein building blocks). When GABA binds, channel opening usually increases chloride conductance (the flow of chloride ions into the cell) and reduces the probability that a mature neurone will fire. Benzodiazepines bind at an allosteric site (a binding site separate from the one GABA uses) formed by selected alpha and gamma subunits. They increase the receptor response to GABA rather than occupying the GABA site or opening the channel efficiently on their own.
In the standard introductory comparison, benzodiazepines increase the frequency of GABA-associated channel opening, while barbiturates (older sedative drugs) increase opening duration. The real kinetics (timing of channel opening and closing) depend on subunit composition and drug, so this frequency versus duration contrast is a teaching model rather than a complete molecular description. Enhanced inhibition predicts sedation, impaired coordination and memory effects. Combining drugs that depress the central nervous system (slow brain activity), such as a benzodiazepine with an opioid, can produce more dangerous sedation and breathing depression than either alone, because their effects add together by lowering the excitability of the same brain networks.
A benzodiazepine amplifies GABA-dependent channel activity; it is not a substitute transmitter.
SimpleMed original educational diagram
Lithium and Mood Stabilisation
Lithium is an ion with several intracellular actions, not a drug with one settled receptor target. Proposed mechanisms include effects on inositol signalling (a cell-signalling pathway built around the molecule inositol), glycogen synthase kinase 3 (an enzyme that regulates many cell processes), second-messenger systems (chemical relays inside the cell), gene expression and neuronal plasticity. These observations support a network-level account, but no single mechanism should be presented as the complete explanation for mood stabilisation.
The inositol-depletion model illustrates why level of explanation matters. Lithium can inhibit inositol monophosphatase (an enzyme that recycles inositol) and related phosphatases (enzymes that remove phosphate groups), potentially limiting recycling of inositol used for phosphoinositide signalling (signalling that starts from inositol-containing lipids in the cell membrane). Lithium also influences glycogen synthase kinase 3 directly and indirectly. Both observations are experimentally useful, yet each sits upstream of many cell responses and neither maps neatly onto one mood circuit. A biochemical effect can be real without being the sole therapeutic mechanism.
Other medicines described as mood stabilising do not become mechanistically identical to lithium. Valproate (an anti-epileptic medicine also used in bipolar disorder) affects ion channels and inhibitory signalling among several actions; lamotrigine (another anti-epileptic medicine used in bipolar disorder) chiefly alters voltage-gated sodium-channel-dependent transmitter release in the standard introductory model. Their indications, risks and monitoring are clinical topics outside this lesson. The useful pre-clinical point is that a shared therapeutic label can contain distinct molecular starting points.
Drug Action and Network Adaptation
Target engagement (how much of a drug's target is occupied or blocked) can be measured within minutes or hours. A reuptake transporter is inhibited, a D2 receptor is occupied or GABA-A signalling is enhanced. Some consequences are equally early, including sedation, nausea, motor effects or altered arousal. Other effects emerge as feedback systems adjust. Autoreceptors can desensitise (become less responsive), postsynaptic receptor signalling can change, and programmes of gene transcription or synaptic plasticity can reshape circuit responses.
Therapeutic delay (the gap between starting a drug and seeing its clinical benefit) does not mean that the drug is inactive until a fixed date. Onset varies with medicine, outcome and person. Nor does adaptation prove one universal downstream pathway. It means that molecular action and experienced clinical change are observations at different levels and timescales. Good mechanism language separates established target pharmacology from plausible, still incomplete explanations of delayed benefit.
This separation also prevents a common reasoning error. Early nausea after SERT inhibition and later change in mood do not require the same receptor population or circuit, even though both effects began with exposure to one medicine. Likewise, rapid sedation from H1 antagonism does not show that the slower intended response has already occurred. Time course is evidence about mechanism, not merely a waiting instruction.
Target engagement begins the process; feedback and network adaptation unfold on overlapping, variable timescales.
SimpleMed original educational diagram
Tolerance, Dependence and Withdrawal
Tolerance means that repeated exposure produces less effect at the same concentration, or that more exposure is needed for a similar effect. Mechanisms can include receptor regulation, altered coupling, metabolism or learned adaptation, and tolerance need not develop equally to every effect. Physical dependence means the adapted system now responds to drug removal with a withdrawal state. Physical dependence can occur during medically supervised exposure and is not itself the behavioural syndrome of addiction.
Withdrawal is the set of effects that follows reduction or cessation in a dependent system. Rebound excitation (overactivity of neurones) after sustained enhancement of GABAergic (GABA-mediated) inhibition is a clear model: opposing adaptations are unmasked when the enhancer is removed. The pattern depends on drug kinetics (how quickly the drug is absorbed, acts and is cleared), exposure and the adaptation involved. These definitions explain why stopping a drug suddenly can provoke withdrawal effects in a dependent system, without turning this foundation lesson into individual treatment advice.
Deriving Adverse Effects
Adverse effects should be derived from targets wherever possible. H1 antagonism predicts sedation and appetite increase; muscarinic antagonism predicts dry mouth, blurred near vision, constipation and urinary retention; alpha-1 antagonism predicts postural hypotension. D2 blockade in nigrostriatal and tuberoinfundibular pathways predicts motor and prolactin effects. GABA-A enhancement predicts sedation, amnesia (memory loss) and impaired coordination. Transporter inhibition can create early autonomic and gastrointestinal effects before slower adaptation is complete.
The reusable sequence is: identify the molecular target, locate it in a synapse or pathway, predict the immediate cell effect, then ask how feedback and repeated exposure reshape the network. Keep confidence proportional to evidence. Target binding may be well established while the full chain to delayed clinical benefit remains incomplete. That distinction turns psychopharmacology from a catalogue into a physiological map and prepares the mechanism framework for Epilepsy and Anti-epileptic Drugs.
Reviewed by: Dr. Marcus Judge
- 148
